trial

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

NCTId NCT00580125
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 164 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
164 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-11
Primary completion
2008-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
PF-00217830Aripiprazole

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

26 total
Garden Grove, United StatesTorrance, United StatesWashington D.C., United StatesDetroit, United StatesBridgeton, United StatesFlorissant, United StatesSaint Charles, United StatesBrooklyn, United StatesBangalore, IndiaMangalore, IndiaUdupi, IndiaPune, India

Linked catalysts

1
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-002 — primary completion2008-09

Facts & assertions

4 sourced
Enrollment
164
Phase
PHASE2
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
PF-00217830
drug
Aripiprazole
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication